Perspectives
Patients with diabetes show poor adherence therapy for heart disease
Adherence to heart disease drugs dopped by half within one year, increasing risks
May 21, 2019Adherence to add-on therapies for heart disease dropped by half within one year for patients new to diabetes with heart disease, increasing risks for heart attacks or strokes
This study on diabetes looked at members newly diagnosed with diabetes who also had pre-existing cardiovascular disease (ASCVD). Three separate antihyperglycemic drug classes are recommended as add-on therapy for people with diabetes who also have ASCVD.
- Glucagon like peptide-1 agonists (GLP-1)
- Sodium-glucose cotransporter-2 inhibitors (SGLT-2i
- Dipeptidyl peptidase-4 inhibitors (DPP-4i)
All these medications require long-term adherence to reduce complications from ASCVD. But for all the drug classes in the study, adherence dropped off by about half within a year. (Yet the drug manufacturers reported adherence of 90 percent in their clinical trials.)
Related news
Perspectives
July 25, 2024
Quarterly Drug Pipeline: July 2024
Clinical insights and competitive intelligence on anticipated drugs in development
Perspectives
July 22, 2024
Oncology Insights: 2024 ASCO Annual Meeting key findings
Findings from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting will likely lead to clinical practice changes and U.S. Food and Drug Administration (FDA) drug approvals or expansions
Perspectives
July 16, 2024
LISTEN NOW: Beyond the business – Stories of corporate kindness | Pharmacy Friends Podcast
In this episode, we talk about how our employees' help goes beyond our work in health care, aiding in philanthropic efforts